Abstracts tagged "prevention"

Abstract Number: 2026 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients
Shanley O'Brien and Paul Schmidt, Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS
Background/Purpose: Streptococcus pneumoniae is the most common cause of bacterial pneumonia.1 Invasive pneumococcal infections carry a 10% mortality rate, which is higher in the immunosuppressed.1…
Abstract Number: 2250 • 2017 ACR/ARHP Annual Meeting
Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
W. Benjamin Nowell¹, Kayla Jordan², Kelly Gavigan¹, Louis Tharp¹, Jeffrey R. Curtis³ and James Pennebaker⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Texas at Austin, Austin, TX, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Psychology, University of Texas at Austin, Austin, TX
Background/Purpose: Non-adherence to gout medication is high. This may be due in part to patients’ belief that gout is primarily caused by overindulgence in certain…
Abstract Number: 2760 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Ozan Unlu¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Paul R. Fortin⁵, Maria Gerosa⁶, Roger A. Levy⁷, Michelle Lopes⁸, Michelle Petri⁹, Ignasi Rodriguez¹⁰, Maria Tektonidou¹¹, Amaia Ugarte¹², Rohan Willis¹³, Doruk Erkan¹⁴ and , on Behalf of APS ACTION .¹⁵, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁷Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁸Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹⁰Rheumatology, Hospital Clinica, Barcelona, Spain, ¹¹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹²Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ¹⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁵., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 420 • 2016 ACR/ARHP Annual Meeting
Feasibility of a Rheumatology Staff Protocol for Tobacco Cessation Counselling and Quit Line Electronic Referral
Christie M. Bartels¹, Daniel Panyard², Diane Lauver³, Emmanuel Sampene⁴, Zhanhai Li⁵, Robert Adsit⁶, Patrick McBride⁷, Heather Johnson⁷, Kristin Steffen Lewicki⁸ and Edmond Ramly⁹, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁷Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI
Background/Purpose: Smoking is a both a risk factor for developing rheumatoid arthritis (RA) and a predictor of severe, treatment-refractory disease in RA and other rheumatic…
Abstract Number: 422 • 2016 ACR/ARHP Annual Meeting
Developing a Staff-Driven Electronic Smoking Cessation Referral Program in Rheumatology Clinics
Daniel Panyard¹, Edmond Ramly², Andrea Gilmore-Bykovskyi³, Diane Lauver³, Robert Adsit⁴, Courtney Maxcy⁵ and Christie M. Bartels⁶, ¹Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁵University of Wisconsin, Madison, WI, ⁶Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have an increased risk of premature cardiovascular disease (CVD), making comorbid risk factors like…
Abstract Number: 425 • 2016 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic
Alison Bays¹, Renuka R. Nayak², Sara Murray³, Darlene Young⁴, Gabriela Schmajuk⁵, Jinoos Yazdany⁶ and Andrew Gross⁷, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, UCSF, San Francisco, CA, ³Medicine, UCSF, San Francisco, CA, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Patients with autoimmune conditions have higher rates of pneumococcal disease and they are often immunosuppressed. In 2014, the Advisory Committee on Immunization Practices issued…
Abstract Number: 1507 • 2016 ACR/ARHP Annual Meeting
Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: According to the report by WHO, Japan is still in moderately-prevailing countries of TB. The annual incidence of TB in Japan is approximately 15/100,000,…
Abstract Number: 2042 • 2016 ACR/ARHP Annual Meeting
Improving the Overall Pneumococcal Vaccination Rate in Lupus Patients at the Rheumatology Clinic
Shivani Garg¹, Aliza Lipson² and Katina Tsagaris³, ¹Rheumatology, Emory University, Atlanta, GA, ²Rheumatology, EMORY UNIVERSITY, atlanta, GA, ³Rheumatology, EMORY UNIVERSITY, Atlanta, GA
Background/Purpose: The risk of developing invasive pneumococcal pneumonia is 13 times higher in Lupus patients in comparison with general population. CDC anticipates 7.6 Million-Dollar medical…
Abstract Number: 2637 • 2016 ACR/ARHP Annual Meeting
Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example
Leonie E Burgers, Cornelia F Allaart, Tom WJ Huizinga and Annette HM van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Prevention of rheumatoid arthritis (RA) was the aim of several clinical trials performed in undifferentiated arthritis (UA). Overall these trials had negative results. As…
Abstract Number: 2888 • 2016 ACR/ARHP Annual Meeting
Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis
Ivan Castellví¹, Carmen Pilar Simeón², Monica Paola Sarmiento¹, Alfredo Guillen², Cesar Diaz-Torné³, Josep Maria De Llobet Zubiaga¹, Jordi Casademont⁴ and Vicent Fonollosa², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease in which the damage of microcirculation is critical to develop the disease. In SSc, vascular complications…
Abstract Number: 1030 • 2015 ACR/ARHP Annual Meeting
Unwanted Variations in Rheumatology Clinic Rooming: A Time Study Tool and Analysis
Brad Stroik¹, Christie M. Bartels², Diane Lauver³, Patrick McBride⁴, Jon Arnason², Sarah Loring³ and Edmond Ramly^5,6, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin-Madison, Madison, WI, ⁶Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI
Background/Purpose: Facing fixed time for specialty visits, the time staff spends on rooming patients is a premium, but remains poorly understood. We conducted a time…
Abstract Number: 2126 • 2015 ACR/ARHP Annual Meeting
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
George D. Kitas¹, Peter Nightingale², Jane Armitage³, Naveed Sattar⁴, Jill Belch⁵, Deborah P.M. Symmons⁶ and TRACE RA Consortium, ¹Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, ⁴University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, ⁵Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel…
Abstract Number: 2502 • 2015 ACR/ARHP Annual Meeting
Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic
Alison Bays¹, Renuka Nayak², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, UCSF, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Invasive pneumococcal disease is approximately four times more common among patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) compared to healthy counterparts.…
Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Timothy J Schmidt^1,2, J Antonio Avina-Zubieta^2,3,4, Eric C. Sayre³, Michal Abrahamowicz⁵, John M. Esdaile^2,6,7 and Diane Lacaille^8,9,10, ¹Arthritis Research Centre of Canada, Richmind, BC, Canada, ²Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Medicine, University of British Columbia, Vancouver, BC, Canada, ¹⁰University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
Abstract Number: 2307 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention in Rheumatologic Disease: Assessing Screening in a Primary Care Setting
Micaela Bayard¹ and Magdalena Cadet², ¹Rheumatology, New York Hospital of Queens/ Weill Cornell Medical Center, New York, NY, ²Rheumatology and Immunology, Duke University School of Medicine, Durham, NC
Background/Purpose: To determine the proportion of patients diagnosed with rheumatologic disease receiving preventive health care according to US Preventive Services Task Force recommendations with emphasis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].